Access to Pharmaceuticals > The ATP consortium

The ATP consortium

Please check the News page for the latest news 

Access to Pharmaceuticals (ATP) is an EU funded consortium focused on the promotion of Socially Responsible Licencing (SRL) as a means to improve and ensure the availability of essential medicines in the developing world.

Equitable access to pharmaceuticals, particularly for developing countries is an essential human right. Various complex impediments hinder access, which is the subject of ongoing multidisciplinary studies. Intellectual Property and product development are two issues that can be used as tools to address the problem of access, particularly to make patented drugs more affordable and accessible. This proposal addresses three ways of accomplishing this. The first is how academic licensing practices under socially responsible stewardship can ensure that future drugs that have resulted from inventive activity in academia will be available at low cost with improved access in the future. Secondly we will research thoroughly how existing public-private or product-development partnerships are addressing the issue of altruistic development of drugs for relatively neglected populations with unmet health needs and the lessons they have for future drug development. Lastly it addresses the current state and future improvements in compulsory licensing legislative instruments to enable access through generic manufacture of patented drugs. The three routes to access have several significant aspects of overlap which provide for complementary approaches and solutions to access.

  1. Early Stage Research and Development: To develop practical models and best practices for academic policy in IP management and licensing, to minimise barriers for the delivery of pharmaceutical innovation to populations in need. We will work with a variety of stakeholders including Technology Transfer Officers to develop practical and implementable best practices for identification and commercialisation of pharmaceutical innovations that are of importance to health problems of disadvantaged populations.
  2. Product Development: To review existing and evolving practices in Public-Private or Product Development Partnerships (PDP) and to analyse their outcomes in terms of pharmaceutical development. We will identify and develop best practices for successful pharmaceutical partnerships in the commercialisation of therapies for needs that are inadequately met by traditional industry.
  3. Commercial Access to Pharmaceuticals: To identify problems and develop solutions aimed at simplifying processes and removing barriers to trans-national cooperation. This is targeted towards the successful adoption and practical implementation of new legislative instruments to increase access to generic versions of new essential medicines by countries without manufacturing capacity.

Consortium Institutions

St George’s, University of London, UK (co-ordinating institution)
Fiocruz, The Oswaldo Cruz Foundation, Brazil
International Vaccine Institute, South Korea
University of Neuchatel, Switzerland
South African Medical Research Council, South Africa